Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MIST
STRONG SELLREMOVEMilestone Pharmaceuticals Inc. · Healthcare · Canada · $161M · Avg Vol: $2M/d
Milestone Pharmaceuticals is a development-stage cardiovascular biotech. It lacks the scale, cash flow, and quality metrics required by our investment philosophy, and does not benefit from the CDMO manufacturing bottleneck.
COMPANY DESCRIPTION
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for cardiovascular diseases, particularly paroxysmal supraventricular tachycardia (PSVT). Its lead product candidate, etripamil, is a novel, investigational short-acting calcium channel blocker delivered as a nasal spray, offering a potential patient-administered treatment for PSVT. Milestone Pharmaceuticals is a specialized biopharma company aiming to disrupt the treatment paradigm for episodic cardiovascular conditions with an easily administrable, acute therapy.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | 15.0M | 5.0M | 1.0M | 0 | 1.5M | -43.3% |
| EPS | -1.02 | -0.38 | -0.37 | -0.29 | -0.75 | — |
| Shares | 29.9M | 124.5M | 124.5M | 124.5M | 106.2M | +255.3% |
| Debt | 0.7M | 2.5M | 51.8M | 54.8M | 58.4M | 202.4% |
| Equity | 112.6M | 66.3M | 16.8M | 13.1M | 41.8M | -22.0% |
| Op CF | -33.2M | -52.5M | -46.4M | -28.8M | -49.0M | — |
| Inv CF | 70.0M | -57.1M | 4.8M | 8.3M | 11.2M | — |
| Fin CF | 5.1M | 3.1M | 47.8M | 32.1M | 85.5M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MIST are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MIST | Milestone Pharmaceuticals Inc.(you) | $161M | 1 | STRONG SELL |
| NGEN | NervGen Pharma Corp. | $244M | 1 | STRONG SELL |
| HELP | Cybin D/B/A Helus Pharma | $245M | 6 | STRONG SELL |
| ENGN | enGene Therapeutics Inc. | $114M | 8 | STRONG SELL |
| MSLE | Satellos Bioscience Inc. | $119M | 10 | STRONG SELL |
| PMN | ProMIS Neurosciences, Inc. | $97M | 15 | STRONG SELL |
| QNTM.CN | Quantum BioPharma Ltd. | $45M | 2 | STRONG SELL |
| OBI.L | Ondine Biomedical Inc. | $101M | 20 | SELL |
| EDSA | Edesa Biotech, Inc. | $61M | 17 | STRONG SELL |
| MDNA.TO | Medicenna Therapeutics Corp. | $27M | 1 | STRONG SELL |
Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 32.9%